Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia

Journal of Clinical Lipidology

Volumn 3, Issue 3, 2009, Pages 179-186

  Kush, Debra ^a   Kim, Hyo Soo ^b   Hu, Da Yi ^c   Liu, Ji ^a   Sirah, Waheeda ^a   Sapre, Aditi ^a   McCrary Sisk, Christine ^a   Paolini, John F ^a   Maccubbin, Darbie ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Seoul National University Hospital   (South Korea)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Extended release niacin; Flushing; Laropiprant; Mixed hyperlipidemia; Primary hypercholesterolemia

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FLUSHING; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GOUT; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INDIA; KOREA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; URIC ACID BLOOD LEVEL;

EID: 67049172683     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.04.048     Document Type: Article

References (22)

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final report. Circulation 106 (2002) 3143-3421
2. Abbott Pharmaceuticals. Niaspan (niacin extended-release tablets) US prescribing information. Copyright 2005. Available at: http://www.rxabbott.com/pdf/niaspantablet.pdf.
3. The coronary drug project. JAMA 221 (1972) 918
4. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
5. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-bind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
6. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
7. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
8. Knopp R.H., Ginsberg J., Albers J.J., et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34 (1985) 642-650
9. ® (niacin extended-release tablets) US prescribing information. Copyright 2005. Available at: http://www.niaspan.com/pdf/niaspan_pi_ r1.pdf. Accessed April 21, 2009.
10. Illingworth D.R., Stein E.A., Mitchel Y.B., et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med 154 (1994) 1586-1595
11. Mills E., Prousky J., Raskin G., et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial. BMC Clin Pharmacol. 3 (2003) 4-11
12. Cheng K., Wu T.J., Wu K.K., et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 103 (2006) 6682-6687
13. Kaijser L., Eklund B., Olsson A.G., and Carlson L.A. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol. 57 (1979) 114-117
14. Sturino C.F., O'Neill G., Lachance N., et al. Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydro cyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 50 (2007) 794-806
15. Paolini J.P., Mitchel Y.B., Reyes R., et al. Effects of laropiprant on nicotinic acid-induced flushing in dyslipidemic patients. Am J Cardiol. 101 (2008) 625-630
16. Maccubbin D., Bays H.E., Olsson A.G., et al. Lipid-modifying efficacy and tolerability of extended release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 62 (2008) 1959-1970
17. Kush D, Hu D-Y, Ye P, et al. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology. In press.
18. Guyton J.R., and Bays H.E. Safety considerations with niacin therapy. Am J Cardiol. 99 Suppl (2007) 22C-31C
19. Tatò F., Vega G.L., and Grundy S.M. Effects of crystalline nicotinic acid-induced hepatic dysfunction of serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol. 81 (1998) 805-807
20. Rader J.I., Calvert R.J., and Hathcock J.N. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med. 92 (1992) 77-81
21. Grundy S.M., Vega G.L., McGovern M.E., et al. Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes-results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 162 (2002) 1568-1576
22. Elam M.B., Hunninghake D.B., Davis K.B., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA 284 (2000) 1263-1270